Reagent for tumor imaging and therapy

An oligopeptide comprising from 4 to 50 peptide units and containing the pentapeptide tyr-leu-asp-val-tyr, wherein the peptide is attached to a radioactive label or cytotoxin, and wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing an leu-asp-val (LDV) binding site.

An oligopeptide comprising from 4 to 50 peptide units and containing the nonapeptide leu-asp-val-gly-gly-gly-gly-ser-tyr, wherein the peptide is attached to a radioactive label or cytotoxin, and wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing an leu-asp-val (LDV) binding site.

An oligopeptide comprising the tridecapeptide having the sequence Tyr-Gly-Gly-Leu-Asp-Val-Gly-Leu-Asp-Val-Gly-Gly-Tyr (YGGLDVGLDVGGY) SEQ ID No. 2, wherein the oligopeptide is attached to a radioactive label or cytotoxin and wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing an leu-asp-val (LDV) binding site.

An oligopeptide comprising from 4 to 50 peptide units and containing the pentapeptide tyr-leu-asp-val-tyr, wherein the oligopeptide is labelled with a radioactive label, wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing an leu-asp-val (LDV) binding site.

An oligopeptide comprising from 4 to 50 peptide units and containing the nonapeptide leu-asp-val-gly-gly-gly-gly-ser-tyr, wherein the oligopeptide is labelled with a radioactive label, and wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing an leu-asp-val (LDV) binding site.

An oligopeptide comprising from 4 to 50 peptide units and containing the tridecapeptide SEQ ID No. 2, wherein the oligopeptide is labelled with a radioactive label, and wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing an leu-asp-val (LDV) binding site.

An anti-tumor therapeutic compound comprising an oligopeptide having from 4 to 50 peptide units and having as a triplet therein the amino acid sequence leu-asp-val (LDV), wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing a leu-asp-val (LDV) binding site and wherein the oligopeptide is chemically linked to or conjugated with a cytotoxin.

A diagnostic reagent for in vivo tumor imaging comprising an intravenously administrable liquid carrier containing an effective amount of a radioactively labelled oligopeptide having from 4 to 50 peptide units and having as a triplet the therein the amino acid sequence leu-asp-val (LDV), wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing a leu-asp-val (LDV) binding site.

An anti-tumor therapeutic reagent comprising an intravenously administrable liquid carrier comprising an effective amount of a cytotoxic oligopeptide having from 4 to 50 peptide units and having as a triplet therein the amino acid sequence leu-asp-val (LDV), wherein the oligopeptide is capable of binding in-vivo with pathological tissue containing leu-asp-val (LDV) binding sites, and wherein the oligopeptide is chemically linked to or conjugated with a cytotoxin.

A method of in vivo tumor imaging which comprises intravenously administering to the patient an effective amount of a radioactively labelled oligopeptide having from 4 to 50 peptide units and having as a triplet therein the amino acid sequence leu-asp-val (LDV), wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing a leu-asp-val (LDV) binding site and radiographically detecting the bound label.

A method of treating tumors in vivo which comprises intravenously administering to the patient an effective amount of a cytotoxic oligopeptide having from 4 to 50 peptide units and having as a triplet therein the amino acid sequence leu-asp-val (LDV), wherein the oligopeptide is capable of binding in-vivo with pathological tissues containing a leu-asp-val (LDV) binding site and wherein the oligopeptide is attached or conjugated with a cytotoxin.